A model-based cost-effectiveness analysis of pharmacogenomic panel testing in cardiovascular disease management: preemptive, reactive, or none? - Concepedia

Concepedia

Publication | Open Access

A model-based cost-effectiveness analysis of pharmacogenomic panel testing in cardiovascular disease management: preemptive, reactive, or none?

DOI Full Paper Access

53

Citations

21

References

2020

Year

Ye Zhu, James P. Moriarty, Kristi M. Swanson, Paul Y. Takahashi, Suzette J. Bielinski, Richard Weinshilboum, Liewei Wang, Bijan J. Borah

Genetics in Medicine

Abstract

Compared with usual care, preemptive PGx panel testing was cost-effective in cardiovascular disease management.

References

	Year	Citations

Page 1